公开(公告)号：US20250011473A1

公开(公告)日：2025-01-09

申请号：US18755124

申请日：2024-06-26

Applicant: UCB BIOPHARMA SRL

Inventor： Ralph ADAMS ,  Thomas Allen CESKA ,  Anna Marie DAVIES ,  Alistair James HENRY ,  Xiaofeng LIU ,  James Michael MCDONNELL ,  Brian John SUTTON ,  Marta Katarzyna WESTWOOD

IPC: C07K16/42 ,  A61P37/08 ,  C07K14/735 ,  C07K16/28

Abstract: The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the FcεRI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the Cε2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the Cε2 domain of IgE) and/or the ability to disassociate IgE from the FcεRI receptor for instance at pharmaceutically-relevant concentrations. In one aspect, improved or novel treatments for IgE mediated disorders are disclosed in which IgE is targeted (for instance free IgE and/or IgE complexed with the FcεRI receptor).

公开(公告)号：US20230176071A1

公开(公告)日：2023-06-08

申请号：US17923904

申请日：2021-05-06

Applicant: UCB BIOPHARMA SRL

Inventor： Anastasios SPILIOTOPOULOS ,  David James MCMILLAN ,  Michael John Wright ,  Sebastian KELM ,  Xiaofeng LIU ,  Daniel John LIGHTWOOD

IPC: G01N33/68

CPC classification number: G01N33/6857

Abstract: A method of identifying of amino-acid residues on a target protein that form a binding site of a molecule of interest. Such method relies on selection of relevant patches of solvent-accessible residues and testing of an array of mutated proteins for changes of binding properties. Such method is useful for determining binding sites (epitopes) of antibodies, ligands and related molecules.

公开(公告)号：US20220235146A1

公开(公告)日：2022-07-28

申请号：US17541932

申请日：2021-12-03

Applicant: UCB BIOPHARMA SRL

Inventor： Ralph ADAMS ,  Thomas Allen CESKA ,  Anna Marie DAVIES ,  Alistair James HENRY ,  Xiaofeng LIU ,  James Michael MCDONNELL ,  Brian John SUTTON ,  Marta Katarzyna WESTWOOD

IPC: C07K16/42 ,  C07K16/28 ,  C07K14/735 ,  A61P37/08

Abstract: The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the FcεRI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the Cε2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the Cε2 domain of IgE) and/or the ability to disassociate IgE from the FcεRI receptor for instance at pharmaceutically-relevant concentrations. In one aspect, improved or novel treatments for IgE mediated disorders are disclosed in which IgE is targeted (for instance free IgE and/or IgE complexed with the FcεRI receptor).